Trisomy 21 with t(5; 11) chromosomal translocation as new unfavorable cytogenetic abnormalities in pediatric acute myeloid leukemia type M2: One case report of nine-year follow-up and literature review

Abstract

We report one case of pediatric acute myeloid leukemia type 2 (AML-M2) who presented with karyotypic aberration of trisomy 21 with the t(5;11) chromosomal translocation. The patient achieved complete remission after two cycles of chemotherapy of daunorubicin, cytarabine and etoposide. Then, follow-up cytogenetic analysis from bone marrow cell cultures demonstrated a normal karyotype of 46, XY. After 9 years, the patient relapsed and the karyotypic abnormalities of trisomy 21 with t(5;11) reappeared. It was concluded that trisomy 21 with t(5; 11) is a new unfavorable cytogenetic aberration in AML-M2.

Keywords

acute myeloid leukemia / trisomy 21 / t(5;11) chromosomal translocation / prognosis

References

[1] von NeuhoffC, ReinhardtD, SanderA, et al. . Prognostic impact of specific chromosomal aberrations in a large group of pediatric patients with acute myeloid leukemia treated uniformly according to trial AML-BFM 98. J Clin Oncol, 2010, 28(16): 2682-2689

[2] GrimwadeD. The clinical significance of cytogenetic abnormalities in acute myeloid leukaemia. Best Pract Res Clin Haematol, 2001, 14(3): 497-529 PMID: 11640867

[3] ArberDA, SteinAS, CarterNH, et al. . Prognostic impact of acute myeloid leukemia classification: importance of detection of recurring cytogenetic abnormalities and multilineage dysplasia on survival. Am J Clin Pathol, 2003, 119(5): 672-680 PMID: 12760285

[4] IzraeliS, RainisL, HertzbergL, et al. . Trisomy of chromosome 21 in leukemogenesis. Blood Cells Mol Dis, 2007, 39(2): 156-159 PMID: 17532652

[5] WeiCH, YuIT, TzengCH, et al. . Trisomy 21 in acute myeloid leukemia. Cancer Genet Cytogenet, 1996, 86(2): 177-180 PMID: 8603351

[6] RabinKR, WhitlockJA. Malignancy in children with trisomy 21. Oncologist, 2009, 14(2): 164-173 PMID: 19176633 PMCID: 2761094

[7] JajuRJ, FidlerC, HaasOA, et al. . A novel gene, NSD1, is fused to NUP98 in the t(5; 11)(q35; p15. 5) in de novo childhood acute myeloid leukemia. Blood, 2001, 98(4): 1264-1267 PMID: 11493482

[8] BorkhardtA, BojesenS, HaasOA, et al. . The human GRAF gene is fused to MLL in a unique t(5; 11)(q31; q23) and both alleles are disrupted in three cases of myelodysplastic syndrome/acute myeloid leukemia with a deletion 5q. Proc Natl Acad Sci USA, 2000, 97(16): 9168-9173 PMID: 10908648 PMCID: 16840

[9] RaimondiSC, ChangMN, RavindranathY, et al. . Chromosomal abnormalities in 478 children with acute myeloid leukemia: clinical characteristics and treatment outcome in a cooperative pediatric oncology group study—POG 8821. Blood, 1999, 94(11): 3707-3716 PMID: 10572083

[10] SchanzJ, TüchlerH, SoleF, et al. . New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol, 2012, 30(8): 820-829 PMID: 22331955 PMCID: 4874200

[11] GangulyBB, KadamNN, MandalPK. Complexity of chromosomal rearragements in Down syndrome leukemia. J Cancer Res Ther, 2017, 13(2): 381-383 PMID: 28643766

[12] SchultzKA, ChenL, Kunin-BatsonA, et al. . Health-related quality of life (HR-QOL) and chronic health conditions in survivors of childhood acute myeloid leukemia (AML) with Down syndrome (DS): A report from the Children’s Oncology Group. J Pediatr Hematol Oncol, 2017, 39(1): 20-25 PMID: 27906794 PMCID: 5161561

[13] GrimwadeD, HillsRK, MoormanAV, et al. . Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities amongst 5,876 younger adult patients treated in the UK Medical Research Council trials. Blood, 2010, 116(3): 354-365 PMID: 20385793

[14] StratiP, DaverN, RavandiF, et al. . Biological and clinical features of Trisomy 21 acute myeloid leukemia. Clin Lymphoma Myeloma Leuk, 2013, 13(2): 276-281

[15] HuntlyBJ, GillilandDG. Leukaemia stem cells and the evolution of cancer-stem-cell research. Nat Rev Cancer, 2005, 5(4): 311-321 PMID: 15803157

[16] DingL, LeyTJ, LarsonDE, et al. . Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature, 2012, 481(7382): 506-510 PMID: 22237025 PMCID: 3267864

[17] GreavesM, MaleyCC. Clonal evolution in cancer. Nature, 2012, 481(7381): 306-313 PMID: 22258609 PMCID: 3367003

[18] AdamakiM, VlahopoulosS, LambrouGI, et al. . Aberrant AML1 gene expression in the diagnosis of childhood leukemias not characterized by AML1-involved cytogenetic abnormalities. Tumor Biol, 2017, 39(3): 1010428317694308

[19] RoumierC, FenauxP, LafageM, et al. . New mechanisms of AML1 gene alteration in hematological malignancies. Leukemia, 2003, 17(1): 9-16 PMID: 12529654

[20] BénéMC, GrimwadeD, HaferlachC, et al. . Leukemia diagnosis: today and tomorrow. Eur J Haematol, 2015, 95(4): 365-373 PMID: 26110830

[21] BradburyC, HoultonAE, AkikiS, et al. . Prognostic value of monitoring a candidate immunophenotypic leukemic stem/progenitor cell population in patients allografted for acute myeloid leukemia. Leukemia, 2015, 29(4): 988-991 PMID: 25425198

[22] ChiltonL, HarrisonCJ, AshworthI, et al. . Clinical relevance of failed and missing cytogenetic analysis in acute myeloid leukaemia. Leukemia, 2017, 31(5): 1234-1237 PMID: 28111469

[23] RomeroD. Haematological cancer: MRD assessment-guiding decisions for patients with AML. Nat Rev Clin Oncol, 2016, 13(3): 136

[24] StreeterOEJr, BeronPJ, LyerPN, et al. . Precision medicine: Genomic profiles to individualize therapy. Otolaryngol Clin North Am, 2017, 50(4): 765-773 PMID: 28527522

[25] TomlinsonB, LazarusHM. Enhancing acute myeloid leukemia therapy-monitoring response using residual disease testing as a guide to therapeutic decision-making. Expert Rev Hematol, 2017, 10(6): 563-574 PMID: 28475434